Literature DB >> 22134751

Sentinel node navigation surgery attenuates the functional disorders in early gastric cancer.

Yoshihisa Yaguchi1, Hironori Tsujimoto, Isao Kumano, Risa Takahata, Yusuke Matsumoto, Kazumichi Yoshida, Hiroyuki Horiguchi, Satoshi Ono, Takashi Ichikura, Junji Yamamoto, Kazuo Hase.   

Abstract

The purpose of this study was to evaluate the merits of the sentinel node (SN)-navigated reduced gastrectomy (SNRG) procedure. The subjects (sT1N0) were divided into the SNRG group (n=34) and the GL group, that consisted of patients which underwent gastrectomy according to the Japanese Gastric Cancer Association guidelines (n=33). We compared the area of the resected stomach and evaluated their body weight changes, and the results of a questionnaire survey about postoperative symptoms, and nutritional effects by blood tests administered at postoperative months (POM) 3, 6 and 12. The median area of the resected stomach was 104 cm2 in the SNRG group vs. 192 cm2 in the GL group. The body weight loss ratio was -5.9±5.8 vs. -9.3±4.1% at POM 3, and the henoglobin (g/dl) change rate was -1.1±7.9 vs. -6.4±6.5% at POM 12 in the SNRG and GL groups, respectively. There were no significant differences regarding the passage of food, reflux, the incidence of dumping syndrome, digestive and excretory function, or general condition and the satisfaction levels of the patients. In conclusion, SNRG has some advantages over GL in terms of postoperative disorders for at least one year after surgery, and is the recommended choice of a surgical procedure for early gastric cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22134751     DOI: 10.3892/or.2011.1568

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  1 in total

Review 1.  Potential mechanisms of tumor progression associated with postoperative infectious complications.

Authors:  Hironori Tsujimoto; Minako Kobayashi; Hidekazu Sugasawa; Satoshi Ono; Yoji Kishi; Hideki Ueno
Journal:  Cancer Metastasis Rev       Date:  2021-01-03       Impact factor: 9.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.